South San Francisco, CA, United States of America

Binqing Wei

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 6 CIPO patents and 25 EPO patents. Top assignees: Genentech, Inc., Medimmune Limited, F. Hoffmann-La Roche Ag. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Binqing Wei. Retrieved from https://idiyas.com/inventor/binqing-wei-w0epgdsb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 11)

EPO Patents = 25 (Patent Applications = 38)

Average Co-Inventor Count = 7.7

ph-index = 4

Forward Citations = 89(Granted Patents)

Company Filing History:

F. Hoffmann-La Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12338256 - Aza-tetracyclic oxazepine compounds and uses thereof (2025-06-24),

4. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

5. 12152040 - Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer (2024-11-26),

6. 11692043 - Peptidomimetic compounds and antibody-drug conjugates thereof (2023-07-04),

7. 11242344 - (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof (2022-02-08),

8. 10576164 - Pyrrolobenzodiazepines and conjugates thereof (2020-03-03),

9. 10533058 - Peptidomimetic compounds and antibody-drug conjugates thereof (2020-01-14),

10. 9821074 - Pyrrolobenzodiazepines and conjugates thereof (2017-11-21),

11. 9649390 - Pyrrolobenzodiazepines and conjugates thereof (2017-05-16),

12. 8673952 - Benzoxepin PI3K inhibitor compounds and methods of use (2014-03-18),

13. 8263633 - Benzoxepin PI3K inhibitor compounds and methods of use (2012-09-11),

Title: The Innovations of Inventor Binqing Wei

Introduction: Binqing Wei is a prominent inventor based in South San Francisco, California. With an impressive portfolio of 12 patents, he has made significant contributions to the fields of medicinal chemistry and cancer therapeutics. His work focuses on innovative compounds that have the potential to revolutionize treatments for various health conditions.

Latest Patents: Among his most recent patents, Wei has developed isoquinoline compounds aimed at treating HPK1-dependent disorders. These compounds, detailed in his patent for "Isoquinoline compounds and uses thereof," serve as inhibitors of hematopoietic kinase 1 (HPK1) and are crucial in enhancing immune responses. The patent not only discusses the compounds themselves but also outlines methods for treating associated disorders and preparation techniques. Additionally, his work on "Aza-tetracyclic oxazepine compounds and uses thereof" presents promising aza-tetracyclic oxazepinyl compounds that are useful in treating various cancers, further showcasing his expertise in providing innovative solutions to serious health issues.

Career Highlights: Binqing Wei has established himself in the biotechnology sector through his work at notable companies such as Genentech, Inc. and Medimmune Limited. His career reflects a commitment to pushing the boundaries of medical science, particularly in the development and application of new therapeutic agents.

Collaborations: Throughout his career, Wei has collaborated with respected colleagues like Thomas Pillow and Philip Wilson Howard. These partnerships have contributed to his research endeavors and have helped enhance the impact of his innovations in the pharmaceutical industry.

Conclusion: Binqing Wei's contributions to science and medicine through his patented innovations are noteworthy. His isoquinoline and aza-tetracyclic oxazepine compounds represent significant advancements in treatments for immune disorders and cancer. As his career continues to evolve, the impact of his work promises to make a lasting difference in the health care landscape.

Profile summary based on public USPTO records.